Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Endovascular Closure Resolves Trimethylaminuria Caused by Congenital Portosystemic Shunts

  • Received : 2019.04.08
  • Accepted : 2019.06.11
  • Published : 2019.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

This study aimed to report three new cases of an association between two rare conditions, congenital portosystemic shunts (CPSS) and trimethylaminuria (TMAU), and the efficacy of endovascular closure of the CPSS for resolving TMAU. Between November 2014 and April 2017, 15 patients with CPSS were enrolled in this prospective study to assess the efficacy of percutaneous endovascular shunt closure. Three patients presented with clinical symptoms of TMAU that were confirmed by urine analysis of trimethylamine (TMA) and TMA n-oxide. One year after endovascular closure of the congenital portosystemic shunt, the same parameters were evaluated were obtained and the values were compared to the pretreatment values. The results indicated the disappearance of clinical symptoms of TMAU and normalization of the urine test parameters in two patients and no changes in one patient, who developed new portosystemic communications.

Keywords

References

  1. Wise PM, Eades J, Tjoa S, Fennessey PV, Preti G. Individuals reporting idiopathic malodor production: demographics and incidence of trimethylaminuria. Am J Med 2011;124:1058-63. https://doi.org/10.1016/j.amjmed.2011.05.030
  2. Mackay RJ, McEntyre CJ, Henderson C, Lever M, George PM. Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clin Biochem Rev 2011;32:33-43.
  3. Mountain H, Brisbane JM, Hooper AJ, Burnett JR, Goldblatt J. Trimethylaminuria (fish malodour syndrome): a "benign" genetic condition with major psychosocial sequelae. Med J Aust 2008;189:468. https://doi.org/10.5694/j.1326-5377.2008.tb02129.x
  4. Messenger J, Clark S, Massick S, Bechtel M. A review of trimethylaminuria: (fish odor syndrome). J Clin Aesthet Dermatol 2013;6:45-8.
  5. Cashman JR. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 2004;9:574-81. https://doi.org/10.1016/S1359-6446(04)03136-8
  6. Mitchell SC, Smith RL. Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos 2001;29(4 Pt 2):517-21.
  7. Christodoulou J. Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder. J Paediatr Child Health 2012;48:E153-5. https://doi.org/10.1111/j.1440-1754.2010.01978.x
  8. Ono H, Mawatari H, Mizoguchi N, Eguchi T, Sakura N. Clinical features and outcome of eight infants with intrahepatic porto-venous shunts detected in neonatal screening for galactosaemia. Acta Paediatr 1998;87:631-4. https://doi.org/10.1111/j.1651-2227.1998.tb01521.x
  9. Gitzelmann R, Forster I, Willi UV. Hypergalactosaemia in a newborn: self-limiting intrahepatic portosystemic venous shunt. Eur J Pediatr 1997;156:719-22. https://doi.org/10.1007/s004310050698
  10. Kanazawa H, Nosaka S, Miyazaki O, Sakamoto S, Fukuda A, Shigeta T, et al. The classification based on intrahepatic portal system for congenital portosystemic shunts. J Pediatr Surg 2015;50:688-95. https://doi.org/10.1016/j.jpedsurg.2015.01.009
  11. Hao Y, Hong X, Zhao X. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital heart disease (Abernethy malformation): a case report and literature review. Oncol Lett 2015;9:695-700. https://doi.org/10.3892/ol.2014.2767
  12. Lautz TB, Shah SA, Superina RA. Hepatoblastoma in children with congenital portosystemic shunts. J Pediatr Gastroenterol Nutr 2016;62:542-5. https://doi.org/10.1097/MPG.0000000000001012
  13. Osorio MJ, Bonow A, Bond GJ, Rivera MR, Vaughan KG, Shah A, et al. Abernethy malformation complicated by hepatopulmonary syndrome and a liver mass successfully treated by liver transplantation. Pediatr Transplant 2011;15:E149-51. https://doi.org/10.1111/j.1399-3046.2010.01337.x
  14. Sato H, Miura M, Yaoita N, Yamamoto S, Tatebe S, Aoki T, et al. Pulmonary arterial hypertension associated with congenital portosystemic shunts treated with transcatheter embolization and pulmonary vasodilators. Intern Med 2016;55:2429-32. https://doi.org/10.2169/internalmedicine.55.6557
  15. Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steimberg C, Losay J, et al. Complications of congenital portosystemic shunts in children: therapeutic options and outcomes. J Pediatr Gastroenterol Nutr 2010;51:322-30. https://doi.org/10.1097/mpg.0b013e3181d9cb92
  16. Bas S, Guran T, Atay Z, Haliloglu B, Abali S, Turan S, et al. Premature pubarche, hyperinsulinemia and hypothyroxinemia: novel manifestations of congenital portosystemic shunts (Abernethy malformation) in children. Horm Res Paediatr 2015;83:282-7. https://doi.org/10.1159/000369395
  17. Gong Y, Zhu H, Chen J, Chen Q, Ji M, Pa M, et al. Congenital portosystemic shunts with and without gastrointestinal bleeding - case series. Pediatr Radiol 2015;45:1964-71. https://doi.org/10.1007/s00247-015-3417-6
  18. Schaeffer DF, Laiq S, Jang HJ, John R, Adeyi OA. Abernethy malformation type II with nephrotic syndrome and other multisystemic presentation: an illustrative case for understanding pathogenesis of extrahepatic complication of congenital portosystemic shunt. Hum Pathol 2013;44:432-7. https://doi.org/10.1016/j.humpath.2012.08.018
  19. Bernard O, Franchi-Abella S, Branchereau S, Pariente D, Gauthier F, Jacquemin E. Congenital portosystemic shunts in children: recognition, evaluation, and management. Semin Liver Dis 2012;32:273-87. https://doi.org/10.1055/s-0032-1329896
  20. Fernandez MS, Gutierrez C, Vila JJ, Lopez A, Ibanez V, Sanguesa C, et al. Congenital intrahepatic portocaval shunt associated with trimethylaminuria. Pediatr Surg Int 1997;12(2-3):196-7. https://doi.org/10.1007/BF01350000